Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find ...

Income investors shouldn't be too worried about the pharma giant cutting its dividend.

Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching ...

Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves ...

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage ...

Pfizer is being tracked as defensive market positioning and a busy regulatory event calendar changes the tone across the broader market. Attention remains on medicines, vaccines, pipeline execution ...

Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far. Merck (NYSE:MRK) leads, Amgen (NASDAQ:AMGN) sits second, and Pfizer (NYSE:PFE) trails as a distant third. Merck ...

Pfizer (NYSE: PFE) reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by stronger-than-expected performance from its non-COVID ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15.03 billion. The company expects the full ...

On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE ...